Last reviewed · How we verify
NCT03613948
Study on the Effects of Mutations Under Inherited Retinal Disease in Korean
trial in Inherited Retinal Dystrophy Primarily Involving Sensory Retina in 280 participants. Completed in 20 January 2021.
20 January 2021
Quick facts
| Lead sponsor | Gangnam Severance Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 280 |
| Start date | 10 April 2018 |
| Primary completion | 20 January 2021 |
| Estimated completion | 20 January 2021 |
| Sites | 1 location across South Korea |
Conditions studied
- Inherited Retinal Dystrophy Primarily Involving Sensory Retina — all drugs for Inherited Retinal Dystrophy Primarily Involving Sensory Retina →
- Inherited Retinal Dystrophy Primarily Involving Retinal Pigment Epithelium — all drugs for Inherited Retinal Dystrophy Primarily Involving Retinal Pigment Epithelium →
Sponsor
Gangnam Severance Hospital
Who can join
Adults 4 Months to 75, any sex, with Inherited Retinal Dystrophy Primarily Involving Sensory Retina or Inherited Retinal Dystrophy Primarily Involving Retinal Pigment Epithelium. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To develop comprehensive genetic maps of inherited retinal diseases in Korean * Establishment of comprehensive genetic database in Koreans with inherited retinal diseases including frequently mutated genes, genotype-phenotype correlations, and visual prognosis."
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
In Silico identification of a common mobile element insertion in exon 4 of RP1.
Won D, Hwang JY, Shim Y, Byeon SH, et al · · 2021 · cited 10× · PMID 34183725 · DOI 10.1038/s41598-021-92834-4
Verify or expand the search:
- PubMed search for NCT03613948
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Inherited Retinal Dystrophy Primarily Involving Sensory Retina
Currently open trials in the same condition.
- NCT05626920 — Disulfiram for Treatment of Retinal Degeneration · Phase 1, PHASE2 · recruiting
Other Gangnam Severance Hospital trials
Trials by the same sponsor.
- NCT07505628 — AI-based Rehabilitation for Hip and Knee Surgery Patients · NA · not yet recruiting
- NCT07311122 — Endocrine Therapy Base on 21-gene RS · not yet recruiting
- NCT07011823 — Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC · Phase 2 · not yet recruiting
- NCT07211451 — Axillary Nodal Burden in HER2+ and TNBC · completed
- NCT06839716 — Comparison of Ropivacaine-Poloxamer 407 Hydrogel and TAP Block for Postoperative Pain Management in Laparoscopic/Robotic · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03613948 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gangnam Severance Hospital
- Last refreshed: 25 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03613948.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing